Tuesday, September 29, 2020 12:02:45 PM
Recent AKBA News
- Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease • PR Newswire (US) • 11/14/2024 01:00:00 PM
- Akebia Therapeutics to Present at the Jefferies London Healthcare Conference • PR Newswire (US) • 11/12/2024 01:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/08/2024 07:17:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 12:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 12:05:26 PM
- Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 11/07/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 11/01/2024 08:05:00 PM
- Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 11/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/22/2024 12:05:56 PM
- Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 10/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 11:36:10 AM
- Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 • PR Newswire (US) • 10/15/2024 12:00:00 PM
- CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 • PR Newswire (US) • 10/10/2024 12:00:00 PM
- Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 10/07/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 10/01/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:10 AM
- Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 09/05/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 09/03/2024 08:16:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/03/2024 08:07:59 PM
- Akebia Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/26/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:52:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:18 AM
- Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 11:00:00 AM
- Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 08/02/2024 12:00:00 PM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
FEATURED North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • Nov 18, 2024 9:00 AM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM